InflaRx (IFRX) Stock: Buy, Sell, or Hold?
IFRX - InflaRx N.V. Common Stock
$1.72
0.01 (0.58%)
▲
5d:
-8.99%
30d:
-24.89%
90d:
-18.48%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When IFRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IFRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IFRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IFRX is currently trading at $1.72, which is considered oversold relative to its 30-day fair value range of $1.89 to $2.26.
Technical Outlook: Technically, IFRX is in a downtrend. The price is currently testing key support at $1.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IFRX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.71 (+348.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IFRX is in a downtrend. The price is currently testing key support at $1.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IFRX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.71 (+348.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.89 -
$2.26
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 348.5% below Wall St target ($7.71)
- CAUTION: Bottoming setup, but lagging the sector by 37% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.89 -
$2.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.71
Resistance Level
$2.19
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.97
Wall Street Target
$7.71
(+348.5%)
Revenue Growth (YoY)
-80.8%
Share & Embed Analysis
Last updated: October 03, 2026 3:24 PM ET
Data refreshes hourly during market hours. Next update: 4:24 PM
Data refreshes hourly during market hours. Next update: 4:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IFRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
